An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Sia Viborg Lindskrog; Frederik Prip; Philippe Lamy; Ann Taber; Clarice S. Groeneveld; Karin Birkenkamp-Demtröder; Jørgen Bjerggaard Jensen; Trine Strandgaard; Iver Nordentoft; Emil Christensen; Mateo Sokac; Nicolai J. Birkbak; Lasse Maretty; Gregers G. Hermann; Astrid C. Petersen; Veronika Weyerer; Marc Oliver Grimm; Marcus Horstmann; Gottfrid Sjödahl; Mattias Höglund; Torben Steiniche; Karin Mogensen; Aurélien de Reyniès; Roman Nawroth; Brian Jordan; Xiaoqi Lin; Dejan Dragicevic; Douglas G. Ward; Anshita Goel; Carolyn D. Hurst; Jay D. Raman; Joshua I. Warrick; Ulrika Segersten; Danijel Sikic; Kim E.M. van Kessel; Tobias Maurer; Joshua J. Meeks; David J. DeGraff; Richard T. Bryan; Margaret A. Knowles; Tatjana Simic; Arndt Hartmann; Ellen C. Zwarthoff; Per Uno Malmström; Núria Malats; Francisco X. Real; Lars Dyrskjøt

doi:10.1038/s41467-021-22465-w

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Sia Viborg Lindskrog, Frederik Prip, Philippe Lamy, Ann Taber, Clarice S. Groeneveld, Karin Birkenkamp-Demtröder, Jørgen Bjerggaard Jensen, Trine Strandgaard, Iver Nordentoft, Emil Christensen, Mateo Sokac, Nicolai J. Birkbak, Lasse Maretty, Gregers G. Hermann, Astrid C. Petersen, Veronika Weyerer, Marc Oliver Grimm, Marcus Horstmann, Gottfrid Sjödahl, Mattias HöglundTorben Steiniche, Karin Mogensen, Aurélien de Reyniès, Roman Nawroth, Brian Jordan, Xiaoqi Lin, Dejan Dragicevic, Douglas G. Ward, Anshita Goel, Carolyn D. Hurst, Jay D. Raman, Joshua I. Warrick, Ulrika Segersten, Danijel Sikic, Kim E.M. van Kessel, Tobias Maurer, Joshua J. Meeks, David J. DeGraff, Richard T. Bryan, Margaret A. Knowles, Tatjana Simic, Arndt Hartmann, Ellen C. Zwarthoff, Per Uno Malmström, Núria Malats, Francisco X. Real, Lars Dyrskjøt^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

131 Citationer (Scopus)

56 Downloads (Pure)

Abstract

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

Originalsprog	Engelsk
Artikelnummer	2301
Tidsskrift	Nature Communications
Vol/bind	12
Udgave nummer	1
Antal sider	18
ISSN	2041-1723
DOI	https://doi.org/10.1038/s41467-021-22465-w
Status	Udgivet - 16 apr. 2021

Bibliografisk note

Funding Information:
L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J.J.M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix. R.T.B. has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma and QED Therapeutics. The following authors declare no competing interests: S.V.L., F.P., P.L., A.T., C.S.G., K.B.D., T.S., I.N., E.C., M.S., N.J.B., L.M., G.G.H., A.C.P., V.W., M.O.G., M.H., G.S., M.H., T.S., K.M., A.R., R.M., B.J., X.L., D.D., D.G.W., A.G., C.D.H., J.I.W., U.S., D.S., K.E.M.K., T.M., D.J.D., M.A.K., T.S., A.H., E.C.Z., P.U.M., N.M., and F.X.R.

Funding Information:
We thank K.K. Cheng, Maurice P. Zeegers, Nicholas D. James, Naheema S. Gordon, Ben Abbotts and Roland Arnold for work involved in generating the Birmingham RNA-Seq validation cohort. S.V.L., F.P., and L.D. are supported by the following funding sources: Aarhus University, The Danish Cancer Biobank, The Health Research Foundation of Central Denmark Region, The Danish Cancer Society. N.M. and F.X.R. are supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI18/ 01347), Asociación Española Contra el Cáncer (AECC, # GB28012014). D.J.D. is supported by the following funding sources: RSG 17-233–01-TBE from the American Cancer Society, the W.W. Smith Charitable Trust, the Pennsylvania Department of Health via Tobacco CURE Funds, the Ken and Bonnie Shockey Fund for Urologic Research and the Bladder Cancer Support Group at Penn State Health. J.I.W. is supported by the Laurence M. Demers Career Development Professorship in Pathology and Medicine, Pennsylvania State University. J.D.R. is supported by the Ken and Bonnie Shockey Fund for Urologic Research at Penn State Health. J.M. is funded by a SEED Award from the HOPE Foundation, the Department of Defense (W81XWH-18-0257), and the VHA (BX003692-01).

Publisher Copyright:
© 2021, The Author(s).

Adgang til dokumentet

10.1038/s41467-021-22465-wLicens: CC BY 4.0

Lindskrog et al (2021) An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancerForlagets udgivne version, 2,6 MBLicens: CC BY 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

Link to publication in Scopus

Citationsformater

Lindskrog, S. V., Prip, F., Lamy, P., Taber, A., Groeneveld, C. S., Birkenkamp-Demtröder, K., Jensen, J. B., Strandgaard, T., Nordentoft, I., Christensen, E., Sokac, M., Birkbak, N. J., Maretty, L., Hermann, G. G., Petersen, A. C., Weyerer, V., Grimm, M. O., Horstmann, M., Sjödahl, G., ... Dyrskjøt, L. (2021). An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 12(1), Artikel 2301. https://doi.org/10.1038/s41467-021-22465-w

@article{29f4d3548f414117ae72c0c56428f55e,

title = "An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer",

abstract = "The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.",

author = "Lindskrog, {Sia Viborg} and Frederik Prip and Philippe Lamy and Ann Taber and Groeneveld, {Clarice S.} and Karin Birkenkamp-Demtr{\"o}der and Jensen, {J{\o}rgen Bjerggaard} and Trine Strandgaard and Iver Nordentoft and Emil Christensen and Mateo Sokac and Birkbak, {Nicolai J.} and Lasse Maretty and Hermann, {Gregers G.} and Petersen, {Astrid C.} and Veronika Weyerer and Grimm, {Marc Oliver} and Marcus Horstmann and Gottfrid Sj{\"o}dahl and Mattias H{\"o}glund and Torben Steiniche and Karin Mogensen and {de Reyni{\`e}s}, Aur{\'e}lien and Roman Nawroth and Brian Jordan and Xiaoqi Lin and Dejan Dragicevic and Ward, {Douglas G.} and Anshita Goel and Hurst, {Carolyn D.} and Raman, {Jay D.} and Warrick, {Joshua I.} and Ulrika Segersten and Danijel Sikic and {van Kessel}, {Kim E.M.} and Tobias Maurer and Meeks, {Joshua J.} and DeGraff, {David J.} and Bryan, {Richard T.} and Knowles, {Margaret A.} and Tatjana Simic and Arndt Hartmann and Zwarthoff, {Ellen C.} and Malmstr{\"o}m, {Per Uno} and N{\'u}ria Malats and Real, {Francisco X.} and Lars Dyrskj{\o}t",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = apr,

day = "16",

doi = "10.1038/s41467-021-22465-w",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Lindskrog, SV, Prip, F, Lamy, P, Taber, A, Groeneveld, CS, Birkenkamp-Demtröder, K, Jensen, JB, Strandgaard, T, Nordentoft, I, Christensen, E, Sokac, M, Birkbak, NJ, Maretty, L, Hermann, GG, Petersen, AC, Weyerer, V, Grimm, MO, Horstmann, M, Sjödahl, G, Höglund, M, Steiniche, T, Mogensen, K, de Reyniès, A, Nawroth, R, Jordan, B, Lin, X, Dragicevic, D, Ward, DG, Goel, A, Hurst, CD, Raman, JD, Warrick, JI, Segersten, U, Sikic, D, van Kessel, KEM, Maurer, T, Meeks, JJ, DeGraff, DJ, Bryan, RT, Knowles, MA, Simic, T, Hartmann, A, Zwarthoff, EC, Malmström, PU, Malats, N, Real, FX & Dyrskjøt, L 2021, 'An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer', Nature Communications, bind 12, nr. 1, 2301. https://doi.org/10.1038/s41467-021-22465-w

TY - JOUR

T1 - An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

AU - Lindskrog, Sia Viborg

AU - Prip, Frederik

AU - Lamy, Philippe

AU - Taber, Ann

AU - Groeneveld, Clarice S.

AU - Birkenkamp-Demtröder, Karin

AU - Jensen, Jørgen Bjerggaard

AU - Strandgaard, Trine

AU - Nordentoft, Iver

AU - Christensen, Emil

AU - Sokac, Mateo

AU - Birkbak, Nicolai J.

AU - Maretty, Lasse

AU - Hermann, Gregers G.

AU - Petersen, Astrid C.

AU - Weyerer, Veronika

AU - Grimm, Marc Oliver

AU - Horstmann, Marcus

AU - Sjödahl, Gottfrid

AU - Höglund, Mattias

AU - Steiniche, Torben

AU - Mogensen, Karin

AU - de Reyniès, Aurélien

AU - Nawroth, Roman

AU - Jordan, Brian

AU - Lin, Xiaoqi

AU - Dragicevic, Dejan

AU - Ward, Douglas G.

AU - Goel, Anshita

AU - Hurst, Carolyn D.

AU - Raman, Jay D.

AU - Warrick, Joshua I.

AU - Segersten, Ulrika

AU - Sikic, Danijel

AU - van Kessel, Kim E.M.

AU - Maurer, Tobias

AU - Meeks, Joshua J.

AU - DeGraff, David J.

AU - Bryan, Richard T.

AU - Knowles, Margaret A.

AU - Simic, Tatjana

AU - Hartmann, Arndt

AU - Zwarthoff, Ellen C.

AU - Malmström, Per Uno

AU - Malats, Núria

AU - Real, Francisco X.

AU - Dyrskjøt, Lars

PY - 2021/4/16

Y1 - 2021/4/16

N2 - The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

AB - The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85104378401&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-22465-w

DO - 10.1038/s41467-021-22465-w

M3 - Journal article

C2 - 33863885

AN - SCOPUS:85104378401

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2301

ER -

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Abstract

Bibliografisk note

Adgang til dokumentet

AUB Link

Andre filer og links

Fingeraftryk

Citationsformater